^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DNMT inhibitor

    Related drugs:
    14h
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    19h
    Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial. (PubMed, Commun Med (Lond))
    Our findings highlight the potential of epigenetic modulators to re-shape the tumor microenvironment of PROC toward a more inflammed phenotype and may point to approaches to augment immunotherapy response.
    Clinical • P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Platinum resistant
    |
    CD8 (cluster of differentiation 8) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab) • Onureg (azacitidine oral)
    1d
    A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2/3, N=40, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P2/3 trial
    |
    azacitidine
    2d
    A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, University of Chicago
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    cyclophosphamide • decitabine • Proleukin (aldesleukin)
    2d
    A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) (clinicaltrials.gov)
    P2, N=25, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
    |
    EZH2 mutation
    |
    Inqovi (decitabine/cedazuridine)
    4d
    ASTX727-03: Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (clinicaltrials.gov)
    P1/2, N=160, Completed, Taiho Oncology, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Inqovi (decitabine/cedazuridine)
    5d
    Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Pamela Munster | Trial completion date: Feb 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
    |
    PALB2 mutation • CHEK2 mutation
    |
    Lynparza (olaparib) • Inqovi (decitabine/cedazuridine)
    5d
    Hypermethylation-mediated silencing of RASD1 drives multiple myeloma pathogenesis. (PubMed, Blood Res)
    RASD1 is frequently silenced in MM through promoter hypermethylation. This epigenetic inactivation is associated with adverse clinical features and enhanced cell survival, supporting a tumor suppressor role for RASD1 in MM pathogenesis.
    Journal
    |
    RASD1 (Ras Related Dexamethasone Induced 1)
    |
    decitabine
    6d
    PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes (clinicaltrials.gov)
    P1/2, N=72, Active, not recruiting, Otsuka Beijing Research Institute | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Inqovi (decitabine/cedazuridine)
    7d
    The clinical study on individualized treatment for advanced myeloproliferative neoplasms using integrated multi-omics approaches (ChiCTR2500111453)
    P=N/A, N=10, Not yet recruiting, The Second Medical Center of Chinese PLA General Hospital​; The Second Medical Center of Chinese PLA General Hospital?
    New trial
    |
    TP53 (Tumor protein P53) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • CALR (Calreticulin)
    |
    TP53 mutation • ASXL1 mutation • EZH2 mutation
    |
    decitabine
    7d
    A prospective, multiple centers, single arm clinical study on the efficacy and safety of decitabine combined with improved TBF conditioning regimen in patients with myelodysplastic syndrome accompanied by myelofibrosis received Allogeneic hematopoietic stem cell transplantation. (ChiCTR2500114465)
    P2, N=54, Not yet recruiting, The First Affiliated Hospital of Zhejiang University, School of Medicine,; The First Affiliated Hospital of Zhejiang University, School of Medicine,
    New P2 trial
    |
    decitabine • fludarabine IV • thiotepa • busulfan
    7d
    A Prospective, Single-Center, Exploratory Study on the Efficacy and Safety of Ultra-Low-Dose Decitabine Combined with Escalating-Dose Donor Lymphocyte Infusion for Post-Transplant Relapse Prevention in Patients with Bi-allelic TP53 Mutated Myelodysplastic Syndromes (ChiCTR2500114629)
    P2, N=32, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    TP53 mutation
    |
    decitabine